The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
Gunter Von Minckwitz
Consultant or Advisory Role - AbbVie
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Joyce O'Shaughnessy
No relevant relationships to disclose
Eric P. Winer
Research Funding - Genentech
Norman Wolmark
Consultant or Advisory Role - Roche (U); Sanofi (U)
Research Funding - NCI
Charles E. Geyer
No relevant relationships to disclose
Jens Bodo Huober
No relevant relationships to disclose
Sibylle Loibl
Honoraria - AbbVie
William M. Sikov
Consultant or Advisory Role - AbbVie (U)
Michael Untch
No relevant relationships to disclose
Mark D. McKee
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Vincent L. Giranda
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Hope S. Rugo
No relevant relationships to disclose